Affordable Access

deepdyve-link
Publisher Website

An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.

Authors
  • Palit, Victor1
  • Eardley, Ian
  • 1 University Hospital of North Tees, Hardwick Road, Stockton-on-Tees, Cleveland TS19 8PE, UK.
Type
Published Article
Journal
Nature Reviews Urology
Publisher
Springer Nature
Publication Date
Nov 01, 2010
Volume
7
Issue
11
Pages
603–609
Identifiers
DOI: 10.1038/nrurol.2010.165
PMID: 21068761
Source
Medline
License
Unknown

Abstract

The management of erectile dysfunction (ED) has been revolutionized by the discovery of phosphodiesterase 5 (PDE5) inhibitors, which have been commercially available for more than a decade and are the first-line therapeutic option for men with ED. Sildenafil, vardenafil and tadalafil were approved by the European Medicine Agency and the US FDA for the treatment of ED on the back of their high efficacy rates and favorable safety profiles. However, despite the fact that more than 50 million patients with ED worldwide have been successfully treated with one of these PDE5 inhibitors, some men--most notably those with severe neurologic damage, diabetes mellitus or severe vascular disease--are resistant to the currently available drugs and require more-invasive treatments, such as intracavernosal injection therapy. Partly as a consequence of this, research into alternative therapeutic approaches continues, including the development of new PDE5 inhibitors, centrally acting pharmaceutical agents, and application of molecular technologies such as gene therapy and stem cell therapy.

Report this publication

Statistics

Seen <100 times